VIEKIRA PAK
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $13,000 | 1 | 0 |
| 2022 | $188.89 | 9 | 9 |
| 2020 | $9,905 | 14 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13,000 | 1 | 56.3% |
| Consulting Fee | $9,750 | 2 | 42.2% |
| Food and Beverage | $328.98 | 20 | 1.4% |
| Education | $14.80 | 1 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I) | ABBVIE INC. | $13,000 | 0 |
Top Doctors Receiving Payments for VIEKIRA PAK
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $13,000 | 1 |
| , M.D | Internal Medicine | Buffalo, NY | $6,000 | 1 |
| , M.D | Gastroenterology | Catonsville, MD | $3,750 | 1 |
| , M.D., M.S.C.R | Internal Medicine | Dallas, TX | $20.99 | 1 |
| , M.D | Internal Medicine | Dallas, TX | $20.99 | 1 |
| , MD | Gastroenterology | Dallas, TX | $20.99 | 1 |
| , MSN | Nurse Practitioner | Dallas, TX | $20.99 | 1 |
| , M.D | Internal Medicine | Dallas, TX | $20.99 | 1 |
| , MD | Gastroenterology | Philadelphia, PA | $20.99 | 1 |
| , M.D | Transplant Hepatology | Dallas, TX | $20.99 | 1 |
| , ACNP-BC | Acute Care | Nashville, TN | $20.98 | 1 |
| , PA | Medical | Mckinney, TX | $20.98 | 1 |
| , MD | Hepatology | Dallas, TX | $17.58 | 2 |
| , M.D | Medical Toxicology | Washington, DC | $14.80 | 1 |
| , MD | Gastroenterology | Dallas, TX | $14.21 | 1 |
| , D.O | Gastroenterology | Dallas, TX | $14.20 | 1 |
| , M.D | Transplant Hepatology | Dallas, TX | $14.20 | 1 |
| , MD | Internal Medicine | Dallas, TX | $14.20 | 1 |
| , M.D | Infectious Disease | Dallas, TX | $14.20 | 1 |
| , MD | Transplant Hepatology | Wayne, PA | $14.20 | 1 |
| , M.D | Internal Medicine | Dallas, TX | $14.20 | 1 |
| , M.D | Gastroenterology | Dallas, TX | $14.20 | 1 |
| , MD | Rheumatology | Maple Grove, MN | $8.90 | 1 |
Manufacturing Companies
- ABBVIE INC. $13,189
- AbbVie Inc. $9,905
Product Information
- Type Drug
- Total Payments $23,094
- Total Doctors 22
- Transactions 24
About VIEKIRA PAK
VIEKIRA PAK is a drug associated with $23,094 in payments to 22 healthcare providers, recorded across 24 transactions in the CMS Open Payments database. The primary manufacturer is AbbVie Inc..
Payment data is available from 2020 to 2023. In 2023, $13,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for VIEKIRA PAK is "Unspecified" ($13,000, 56.3% of total).
VIEKIRA PAK is associated with 1 research study, including "A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)" ($13,000).